Analysts expect Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) to post ($0.10) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Ekso Bionics’ earnings. Ekso Bionics reported earnings per share of ($0.41) during the same quarter last year, which would indicate a positive year-over-year growth rate of 75.6%. The company is scheduled to announce its next quarterly earnings results on Tuesday, March 6th.
On average, analysts expect that Ekso Bionics will report full year earnings of ($0.81) per share for the current fiscal year. For the next fiscal year, analysts anticipate that the firm will report earnings of ($0.35) per share. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Ekso Bionics.
Ekso Bionics (NASDAQ:EKSO) last posted its earnings results on Wednesday, November 8th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.05). The company had revenue of $1.60 million for the quarter, compared to analyst estimates of $2.40 million. Ekso Bionics had a negative return on equity of 323.00% and a negative net margin of 343.53%.
A number of research firms have recently issued reports on EKSO. ValuEngine upgraded shares of Ekso Bionics from a “strong sell” rating to a “sell” rating in a research note on Friday, November 17th. Zacks Investment Research upgraded shares of Ekso Bionics from a “sell” rating to a “hold” rating in a research note on Tuesday, January 9th.
In other news, insider Russ Angold sold 50,000 shares of the firm’s stock in a transaction dated Wednesday, November 22nd. The shares were sold at an average price of $3.51, for a total transaction of $175,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 3.32% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in the stock. Intellectus Partners LLC increased its position in Ekso Bionics by 5.3% during the second quarter. Intellectus Partners LLC now owns 105,294 shares of the company’s stock worth $244,000 after acquiring an additional 5,294 shares during the period. Carl Domino Inc increased its position in Ekso Bionics by 125.2% during the third quarter. Carl Domino Inc now owns 184,788 shares of the company’s stock worth $224,000 after acquiring an additional 102,734 shares during the period. Vanguard Group Inc. increased its position in Ekso Bionics by 32.9% during the second quarter. Vanguard Group Inc. now owns 711,082 shares of the company’s stock worth $1,650,000 after acquiring an additional 176,197 shares during the period. Finally, National Planning Corp increased its position in Ekso Bionics by 122.2% during the third quarter. National Planning Corp now owns 520,942 shares of the company’s stock worth $620,000 after acquiring an additional 286,492 shares during the period. 6.18% of the stock is currently owned by institutional investors and hedge funds.
Ekso Bionics (EKSO) traded down $0.04 during midday trading on Friday, hitting $1.73. 483,506 shares of the stock were exchanged, compared to its average volume of 1,090,000. The company has a current ratio of 6.09, a quick ratio of 5.73 and a debt-to-equity ratio of 0.18. The firm has a market cap of $106.03, a PE ratio of -1.86 and a beta of 2.01. Ekso Bionics has a one year low of $0.99 and a one year high of $4.77.
COPYRIGHT VIOLATION NOTICE: This news story was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another site, it was copied illegally and reposted in violation of US and international trademark and copyright law. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/14/0-10-eps-expected-for-ekso-bionics-holdings-inc-ekso-this-quarter.html.
Ekso Bionics Company Profile
Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.
Get a free copy of the Zacks research report on Ekso Bionics (EKSO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.